drugset / Trial / NCT01751867

An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome

NCT01751867

Phase 3 Completed 135 enrolled Xian-Janssen Pharmaceutical Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effectiveness and safety of decitabine in the treatment of myelodysplastic syndrome (name of a group of conditions that occur when the blood-forming cells in the bone marrow are damaged) in Chinese patients.

Timeline

Start
2009-08
Primary completion
2011-05
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Decitabine Small molecule 15 mg/m2 Intravenous
Subject Decitabine Small molecule 20 mg/m2 Intravenous